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CHAPTER 1
INTRODUCTION
Two years into the Coronavirus pandemic, methods for testing, vaccination and treatment remain at the forefront of public health research on both the national and international
level. At the core of much of this research lie questions of effectiveness. When newer, faster
tests become available, it is natural to ask if the new product is as good at detecting the virus
as the slower test. When a vaccine that is easier to manufacture or transport or administer
appears, another effectiveness question arises. This time, we would like to know if the new
vaccine provides as much protection as the first. Indeed, as is often the case in medicine,
the social sciences and in industry, the question of comparative effectiveness is key.
Elementary hypothesis testing methods provide a foundation for answering such questions, but a more nuanced approach known as non-inferiority testing can take into account
more structure. In particular, there are times when the benefits to a new product are so
desirable, medical experts may be willing to tolerate a small drop in effectiveness. For
instance, if a drug showed 90% effectiveness at fighting disease, but had a host of severe
side-effects, a new drug that exhibits no side-effects might be largely preferable as long as
it is at least 85% effective, say. The goal then is not necessarily to establish the new drug
is superior (although it very well could be), but to establish that it is non-inferior.
There is a wealth of articles in the literature concerning non-inferiority testing, both in
the frequentist and Bayesian arenas. For those in industry, FDA guidelines provide insight
on non-inferiority clinical trials [1, 6]. In 2017, Althunian et al. published an overview
pertaining to defining the non-inferiority margin [3]. The effect of programmable bacteria
on tumor regression was studied using non-inferiority techniques by Chowdhury et al. in
2019 [5]. Samiran Ghosh et al. explored non-inferiority with Poisson distributed outcomes
in 2020 [10]. Santu Ghosh et al., in 2017, published a paper exploring transformations of
non-normal distributions [11], as well as a paper giving a hierarchical testing procedure
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in 2022 [12]. In 2011, Hida and Tango wrote about non-inferiority testing with a prespecified margin [15]. Kieser and Friede, in 2011, considered binary endpoints [16]. Koch
and Röhmel, in 2004, described three-armed non-inferiority testing as the “gold standard”
of testing [17]. Mütze et al. considered negative binomially distributed endpoints in 2009
[19]. Pigeot et al., in 2003, contributed to literature by studying three-armed non-inferiority
testing with placebo [20].
A Bayesian perspective, while not the focus of this work, does lend itself to the noninferiority method as well. Gamalo et al. used a Bayesian approach to non-inferiority trials
on anti-infective products in 2014 [8]. Pulak Ghosh et al. also considered three-armed
non-inferiority trials with a Bayesian technique in 2011 [9].
Our aim is to introduce the basic terminology of non-inferiority testing and then propose a new way of conducting these tests. The concept of overlap measure, which is essentially the integral of the minimum of two probability densities, will be defined. Some
examples and applications of the overlap measure will provide an intuitive way of visualizing the measure. The concept of using overlap to address the non-inferiority problem, is,
to our knowledge, a novel one. The proposed test is robust in that it can be used even if the
underlying populations are unknown.
The overlap measure, also known as overlap coefficient, is already a well-studied
quantity. It can be used to assess similarity and has other applications as well. Al-Saleh and
Samawi considered overlap coefficient in two exponential populations in 2007 [2]. Samawi
also used overlap to develop a nonparametric test of symmetry based on overlap in 2011
[21]. Anderson et al., in 2009, used overlap to study polarization [4]. In 2021, FrancoPereira et al. used a binormal approach to perform inference on the overlap coefficient [7].
Giacoletti and Heyse discussed overlap as well as the proportion of similar responses in
terms of vaccination research in 2015 [13]. Lei and Olson utilized overlap to gain insight
into the similarity of two biologics in 2009 [18]. Tanaka-Mizuno et al. applied overlap to
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assessing the similarity of ethnically different populations in terms of pharmacokinetic data
in 2005 [22]. In 2016, Wang and Tian wrote about confidence interval estimation of the
overlap coefficient [23]. There are several other articles in the literature concerning overlap
measure as well.
This thesis, which proposes a test of non-inferiority based on overlap measure, features a simulation chapter that demonstrates how well the proposed test performs. We
will consider the case first where both populations, the reference and the experimental, are
normal. Within this case, different sample sizes will be considered, along with differing
variances. Both the probability of type I error and the power are examined. For a second
case, we turn to non-normal distributions, such as the chi-squared and exponential distributions. We investigate the usefulness of the test as compared to traditional methods. In some
situations the overlap test provides more power then existing tests, which is an encouraging
sign for this new test.
The subsequent sections are organized as follows: Section 2 is dedicated to noninferiority testing, while section 3 is dedicated to overlap measure. Those two concepts
are married together in section 4 where we formally introduce the technique of using overlap measure to test for non-inferiority. Section 5 is reserved for simulation and discussion.
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CHAPTER 2
NON-INFERIORITY TESTING
2.1

D EFINITIONS AND N OTATION

Suppose we have two populations. Further suppose that one of these populations
receives a treatment of established efficacy, while the other population receives a treatment
of unknown efficacy.
Definition 1. The reference population is the group that receives the reference treatment,
which is of known efficacy.
Definition 2. The experimental population is the group that receives the experimental
treatment, which is of unknown efficacy.
• µR is the mean efficacy for the reference population.
• µE is the mean efficacy for the experimental population.
If a researcher wished to establish that the experimental treatment was better than
the reference treatment, such a test would have the form shown below in 2.1 known as a
superiority trial.
H0 : µE ≤ µR

versus Ha : µE > µR

(2.1)

In the medical and pharmaceutical communities, however, a test like the one above
may take on a different form. If the experimental drug has some logistical advantage over
the reference, such as ease of production or transportation, the researcher may relax what
they wish to establish. A margin, which we will call the margin of non-inferiority, is
agreed upon a priori by medical experts. Once this margin is chosen, we can ask whether
the experimental treatment is within this margin of the reference.
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Definition 3. The non-inferiority margin, denoted δN I , is a quantity established by medical experts wherein a treatment within this margin of the reference treatment is deemed to
be of value.
The choice of δN I is of great consequence. If it is chosen to be too small, we may
end up discarding a treatment that is actually of some value in helping patients who might
benefit from the treatment. If it is chosen too large, we may adopt broad use of a treatment
that is much less effective then the reference treatment. For a detailed discussion on how
the margin is chosen in practice, [3] considers ways to make a selection. The test used to
establish non-inferiority is shown in 2.2.
H0 : µE ≤ µR − δN I

versus Ha : µE > µR − δN I

(2.2)

Definition 4. If the test shown in 2.2 is significant, we say the experimental treatment is
non-inferior to reference treatment, or that non-inferiority has been established.
To visualize this, we can divide the real number line into two regions as shown in
Figure 2.1. The mean of the experimental group µE may lie in the inferiority region or the
non-inferiority region.

µR

µ R − δN I

Inferior

Non-inferior

Superior

Figure 2.1: The experimental mean may lie in any region.
Using this language, our null hypothesis amounts to stating that µE falls in the inferiority region. Our alternative states µE falls in the non-inferiority region or the superior
region.

13
CHAPTER 3
THE OVERLAP MEASURE
3.1

A N OVERLAP E XAMPLE

First introduced by M.S. Weizmann in 1970, the quantity known as Overlap Measure
offers insight when it comes to measuring similarity between a pair of non-negative realvalued functions, f1 and f2 . In some contexts, f1 and f2 may represent unknown probability
distributions. Thus, it is helpful to define a quantity that represents an overlap estimate.
Definition 5. The Overlap Measure, ∆, of f1 and f2 is given by
Z
∆ = min{f1 (x), f2 (x)}dx
Note if f1 and f2 are both probability densities, 0 ≤ ∆ ≤ 1.
For instance, suppose f1 and f2 are normal distributions with a standard deviation of
1 unit and further suppose the mean of f1 , denoted by µ1 , is exactly 1 unit larger than the
mean of f2 , denoted by µ2 . In this simple setting, we can readily compute ∆. Figure 3.1
illustrates the desired area.

Figure 3.1: Overlap measure of two normal distributions of equal variance.

2
Since the area is symmetric about x = µ1 +µ
, we find
2


µ1 + µ2
≈ 2 · 0.3085375 = 0.617075
∆ = 2 · Pf 1 X <
2
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3.2

A PPLICATIONS AND AN E STIMATE

In terms of applications, Weizmann himself employed overlap to study the difference
in income among two racial groups. Consequently, the overlap measure is often called
“Weizmann’s Overlap” in his honor.
More recently, in a 2011 paper, Samawi et al. [21] considered the special case where
f2 (x) = f1 (−x). In that setting, the overlap measure can be used to detect symmetry since
a highly symmetric function will have a great deal of overlap with its mirror image. (The
reflection is over the median.)
ˆ of f1 and f2 is given by
Definition 6. The Estimated Overlap Measure, ∆,
ˆ =
∆

Z

min{fˆ1 (x), fˆ2 (x)}dx

where fˆ1 (x) and fˆ2 (x) are estimates for f1 and f2 .
If little or no information about the distribution of f1 and f2 is available, and instead
we have a pair of random samples from f1 and f2 , respectively, it is natural to take fˆ1 (x)
and fˆ2 (x) to be kernel estimates with an appropriate choice of bandwidth. For a straightforward guide on kernel density estimation, the 2006 text Nonparametric and Semiparametric
Models by Härdle et al., is a good starting point [14] . The only kernel function used in this
work will be the Gaussian.

3.3

A SYMPTOTIC R ESULTS

ˆ can be obtained along
According to Anderson (2009), the asymptotic distribution of ∆
the following lines. We start with partitioning the combined support of f1 and f2 into three
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subsets of the real line:
Cf1 ,f2 = {x ∈ R : f1 (x) = f2 (x) > 0}
Cf1 = {x ∈ R : f2 (x) > f1 (x) > 0}
Cf2 = {x ∈ R : f1 (x) > f2 (x) > 0}
Next these three probabilities are defined:
p0 = P (X ∈ Cf1 ,f2 )
p1 = Pf2 (X ∈ Cf1 )
p2 = Pf1 (X ∈ Cf2 )
Asymptotically, as n → ∞,
√

ˆ − ∆) − an
n(∆

=⇒

N (0, v)

where,
an = b

−d/2

||K||22

Z

f 1/2 (x)dx · E min{Z1 , Z2 }

Cf,g

v =

p0 σ02

+

σ12

σ12 = p1 (1 − p1 ) + p2 (1 − p2 )
Z
p
p

2
2
σ0 = ||K||2
cov min{Z1 , Z2 }, min{ρ(t)Z1 + 1 − ρ(t)2 Z3 , ρ(t)Z2 + 1 − ρ(t)2 Z4 } dt
T0
d

T0 = {t ∈ R ||t|| ≤ 1}
Here, K is a kernel function and Zi for i ∈ {1, 2, 3, 4} are standard normal random
variables. The variables b and d represent the bandwidth and dimension, respectively. Also,

||K||22

Z
=

2

Z

K (u)du and ρ(t) =
Rd

K(u)K(u + t)du/||K||2

Rd

In the special case that both f1 and f2 are normal, many simplifications occur. If they
have the same standard deviation, they have just one point of intersection. If they have
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different standard deviations, they have just two points of intersection. This means the set
C1,2 has measure 0. Integrating over a set of 0 measure gives 0, so an = 0. Furthermore,
p0 = P (X ∈ Cf1 ,f2 ) = 0, so v = p0 σ02 + σ12 = σ12 . Thus, we have the test statistic,
z0 =

ˆ − ∆0
∆
∼ N (0, 1)
σˆ1

We can use this to find critical value and reject H0 if z0 > zα .
Finally, we have
√

ˆ − ∆) =⇒ N (0, σ 2 )
n(∆
1

To summarize, the estimated overlap converges in distribution to a normal distribution.
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CHAPTER 4
APPLYING THE OVERLAP MEASURE TO NON-INFERIORITY TESTING
4.1

M OTIVATION

The idea of using overlap measure to study non-inferiority is motivated by noticing an
inverse relationship between the size of the overlap and the distance between the means.
For now, we will assume both populations are unimodal, meaning they have one peak,
and we will assume they are symmetric. Further assume the mean of the experimental
population, µE is less than that of the reference population, µR . Under these conditions,
the smaller the distance between the means, the larger the overlap. Figure 4.1 shows this
relationship with a series of overlap areas.

Figure 4.1: When the means are closer, the overlap is larger

There will be situations when the assumption of symmetry can be dropped which will
allow for the study of skewed distributions. For example, this relationship between means
and overlaps still holds in the case of chi-squared and exponential distributions.
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4.2

H YPOTHESES FOR THE P ROPOSED T EST

With a bit more notation, we will be able to revisit the non-inferiority hypotheses and
rewrite them in terms of overlap. Let fR and fE be the probability density functions for the
reference population and the experimental population, respectively.
Definition 7. The Overlap Margin is the overlap of fR and fE , when µE = µR − δN I .
Denote it by ∆N I . We can think of this quantity as the overlap at the boundary of our
hypothesis test. Let ∆ be the True Overlap of fR and fE .
Using this terminology, the hypotheses for the proposed non-inferiority test are given
in 4.1.
H0 : ∆ ≤ ∆N I

(Small Overlap)

versus Ha : ∆ > ∆N I

(Large Overlap)

(4.1)

As long as ∆ is a decreasing function of µR − µE , the proposed test is equivalent
to the non-inferiority test laid out in Chapter 2. To see this, it is helpful to compare the
hypotheses above to those in 2.2.
Recall that the null hypothesis from 2.2, which states µE ≤ µR − δN I , represents the
assumption the experimental drug is inferior. The proposed null hypothesis above, which
states ∆ ≤ ∆N I , does the same, but with a different connotation. Instead of saying “the
means are farther away than δN I ,” we are saying “the overlap is smaller than ∆N I .”
Also, recall that the alternative hypothesis from 2.2, which states µE > µR − δN I ,
represents the assumption the experimental drug is non-inferior. The proposed alternative
hypothesis above, which states ∆ > ∆N I , again does the same. Here, instead of saying
“the means are closer together than δN I ,” we are saying “the overlap is larger than ∆N I .”
Non-inferiority is established if we reject Ho in favor of Ha .
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CHAPTER 5
RESULTS OF SIMULATION
5.1

I NVESTIGATION

We now turn to learning more about the proposed test through simulation. Primarily,
we are concerned with the probability of type I error, P (Type I), and with the power of the
test. We’ll address these questions for a wide variety of situations by sampling from the
assumed reference population and from the experimental population.
Firstly, we’ll restrict our attention to the case where both samples are drawn from a
normal population. Within this setting, we offer several simulations according to sample
size, specifically, where sample sizes are both set at 100, then where the sample sizes are
both set at 50, and lastly, where the sample sizes are in a 2:1 ratio by setting the experimental sample size at 100 while setting the reference sample size at 50. Each of these three
situations has an effect on the power function. Other possibilities such as a 3:1 ratio or a
3:2 ratio are not part of this work, but they may represent avenues for further research.
We also present simulation results according to several possible choices of spread in
the two populations. Most simple of these is the situation where the standard deviation of
both the reference and experimental populations are equal to 1. Next, is the situation where
the standard deviation of the experimental is “somewhat larger” than the reference. Specifically, they are set at 1.5 and 1 respectively. Lastly, is the situation where the standard
deviation of the experimental is “much larger” than the reference, set at 2 and 1 respectively. One might ask why we did not investigate any situations where the spread of the
reference population is larger than the spread of the experimental. Certainly, this avenue
could be explored with further simulation, but we chose not to at this time because a reference population is typically a well-studied group. On the other hand, an experimental
population is a new group, and it is natural to expect more or equal spread.
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With three situations under consideration for sample size choices and three situations
under consideration for spread, this gives rise to a total of nine sub-cases. For example,
there is one sub-case where the ratio of sample sizes is 2:1 and the variances are equal. For
another example, there is one sub-case where the sample sizes are both 50, but the spread
of the experimental is somewhat larger than that of the reference. Our aim will be to create
a sketch of a power function for each of these nine cases and compare our proposed test to
traditional testing to see how well it does.
Secondly, we will move to the case where both samples are drawn from non-normal
populations. Of course, there are many non-normal distributions we could consider, but at
this time, three in particular will be studied in detail. The chi-squared distribution with 1
degree of freedom, the chi-squared distribution with 3 degrees of freedom, and the exponential distribution with λ = 1.

1.0

Selected non−normal distributions

0.0

0.2

0.4

0.6

0.8

Chi squared 1 df
Chi squared 3 df
Exponential lambda 1

0

2

4

6

8

x

Figure 5.1: Selected non-normal distributions

10

12
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The goal in considering three different non-normal distributions is to get a sense of
how the proposed test does, compared to standard testing, when we sample in a skewed
context. For reference, Figure 5.1 has, in red, the chi-squared with 1 degree of freedom, in
green, the chi-squared with 3 degrees of freedom, and in blue, the exponential. It is with
these non-normal distributions we will see the benefit of using overlap testing.

5.2

S AMPLING FROM N ORMAL P OPULATIONS –M ETHODS

In this section, we present the results we found by sampling from normal populations.
We found these results with the aid of a free software environment known as R to handle
computing and produce graphs of the power functions.
We first fixed the sample sizes for the reference and experimental populations, respectively. Throughout, nR and nE denote these sample sizes. As noted above, we ran
simulations when nR = nE = 100, when nR = nE = 50, and when nR = 50, nE = 100.
Next, we fixed our µR , which is the reference mean, at 2.8. There is no special significance
to this value since any real number can serve in this role, however, it does need to be a fixed
value. The standard deviation of the reference population, σR , was fixed at 1 for ease. Also,
the non-inferiority margin, δN I , was fixed at 1. The mean for the experimental population,
µE is governed by expression below.
µ E = µ R − δN I + ξ

(5.1)

The parameter, ξ in 5.1, can be adjusted at different levels to gain information about
the probability of Type I error and the power of our proposed test. When ξ = 0, the experimental mean is at the boundary of our test. Thus, when we test a large number of
times, the proportion of times H0 is rejected provides an estimate for P (Type I). When
ξ > 0, the experimental mean is within the non-inferiority region. The larger ξ is, the more
firmly within the non-inferiority region, µE lies. Thus, we gain insight into the power of
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the test by choosing a range of positive values for ξ. The values for ξ we investigated in
this work are the values {0, 0.05, 0.2, 0.5, 0.8}. Consequently, these values will be marked
on the horizontal axis in the estimated power functions we will present. The overall appearance of these graphs might be somewhat smoother if we had chosen more than these
five points, however, they provided enough information to see the power tending toward 1
as ξ increases.
In this light, the mean of the experimental population, µE , depends on ξ so it will
take on different values for different simulations. The last value we need to specify is
the standard deviation of the experimental population, σR . As mentioned above, we ran
simulations when σE = 1, when σE = 1.5 and when σE = 2. With these quantities, µR ,
σR , σE , nR , nE , δN I and ξ all specified, we can start sampling.

5.2.1

O BTAINING ∆N I

Initially, we need to find ∆N I by taking these steps:
1. For a fixed µR and δN I , obtain µE = µR + δN I at the boundary of NI hypothesis.
2. Generate samples of specified size for both arms.
3. Estimate the overlap based on the samples.
4. Repeat steps 2 and 3 a large number of times.
5. ∆N I is obtained from the mean of the repeated estimates.
ˆ a bootstrap technique with
To estimate the variance of our estimated overlap, var(∆),
a large number of iterations was used.

5.2.2

ˆ
O BTAINING var(
ˆ ∆)

ˆ
These are the steps taken on each bootstrap iteration to find var(
ˆ ∆).
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• For a given set of data, form both arms, XR and XE ,
1. Take nE and nR observations with replacement from each data set, respectively.
ˆ
2. Estimate the overlap, ∆.
3. Repeat steps 1 and 2 over B times.
ˆ b , b = 1, 2, ..., B.
• Denote these estimates as ∆
ˆ as
• Obtain var(
ˆ ∆)
B
2
1 Xˆ
¯
∆b − ∆
B − 1 b=1

With this estimated variance in place, we can turn our attention toward calculating the
power of the test as well as the probability of type I error. In the steps below, we should
emphasize that if ξ = 0, the proportion of times the hypothesis is rejected tells us the
P (Type I). On the other hand, if ξ > 0, the proportion of times the hypothesis is rejected
tells the power of the test. In general, these are the steps for the normal case:
1. Specify µR , σR , σE , nR , nE , δN I and ξ.
2. Set µE = µR − δN I + ξ
3. Generate XL ∼ N (µL , σL ) with sample size nL for L ∈ {R, E}.
ˆ and var(
ˆ
4. Obtain ∆
ˆ ∆).
5. Get the test statistic, Z.
6. Repeat steps 3 through 5 over M times.
7. Obtain power, or P (Type I), depending on ξ, as the proportion of times the hypothesis is rejected.
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Note that each of these seven steps below was carried out nine times since there are
nine situations we considered. In step 4, kernel density estimation is used to estimate the
density of each population, then the integral of the minimum is taken numerically. We will
organize the results in a series of tables first, then several power function graphs.

5.3

S AMPLING FROM N ORMAL P OPULATIONS -R ESULTS

Below, we see 5.1 indeed has nine entries, and within each cell there are two numbers. Both numbers represent the probability of type I error. However, the numbers inside
the parentheses represent the traditional two-sample hypothesis test while the numbers outside the parentheses represent the new proposed hypothesis test. In other words, we use
the overlap test statistic in order to decide whether or not to reject H0 . Throughout, the
significance level, α = 0.05 is used.
Roughly speaking, all the entries are near our choice of α = 0.05, as expected. In
tables 5.2 through 5.5, the choice of ξ is increasing. That corresponds to placing µE =
µR − δN I + ξ more firmly into the non-inferiority region. In turn, this corresponds to
placing µE more firmly into the rejection region. Consequently, the power, which is the
probability of rejecting H0 ought to increase towards 1. The more rapidly a test does this,
the more powerful it is.
ξ=0

nR = nE = 100

nR = nE = 50

nR = 50, nE = 100

σR = σE = 1

(0.0580) 0.0460

(0.0570) 0.0545

(0.0520) 0.0445

σR = 1, σE = 1.5

(0.0560) 0.0475

(0.0515) 0.0495

(0.0410) 0.0355

σR = 1, σE = 2

(0.0505) 0.0345

(0.0475) 0.0355

(0.0515) 0.0470

Table 5.1: Probability of type I error when sampling from normal, ξ = 0.
What we notice that when the standard deviations are equal, the proposed test is almost
as powerful as the traditional test, especially when both sample sizes at 100. When the
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ξ = 0.05

nR = nE = 100

nR = nE = 50

nR = 50, nE = 100

σR = σE = 1

(0.1090) 0.0860

(0.1028) 0.0833

(0.0935) 0.0825

σR = 1, σE = 1.5

(0.0965) 0.0780

(0.0696) 0.0686

(0.0805) 0.0605

σR = 1, σE = 2

(0.0905) 0.0690

(0.0680) 0.0535

(0.0815) 0.0545

Table 5.2: Power when sampling from normal, ξ = 0.05.
ξ = 0.2

nR = nE = 100

nR = nE = 50

nR = 50, nE = 100

σR = σE = 1

(0.4015) 0.3605

(0.267) 0.231

(0.3155) 0.2580

σR = 1, σE = 1.5

(0.2900) 0.2240

(0.1785) 0.1730

(0.2290) 0.1745

σR = 1, σE = 2

(0.2182) 0.1278

(0.1565) 0.0980

(0.2068) 0.1218

Table 5.3: Power when sampling from normal, ξ = 0.2.
ξ = 0.5

nR = nE = 100

nR = nE = 50

nR = 50, nE = 100

σR = σE = 1

(0.9700) 0.9525

0.804 0.759

0.8915 0.8580

σR = 1, σE = 1.5

(0.8823) 0.7654

(0.6330) 0.4760

(0.7830) 0.5460

σR = 1, σE = 2

(0.7340) 0.3080

(0.4815) 0.1795

(0.6585) 0.2380

Table 5.4: Power when sampling from normal, ξ = 0.5.
ξ = 0.8

nR = nE = 100

nR = nE = 50

nR = 50, nE = 100

σR = σE = 1

(1.000) 1.000

(0.9241) 0.9031

(0.9995) 0.9980

σR = 1, σE = 1.5

(0.9950) 0.9290

(0.9355) 0.7485

0.9845 0.8250

σR = 1, σE = 2

(0.9695) 0.4590

(0.8240) 0.2790

(0.9500) 0.3415

Table 5.5: Power when sampling from normal, ξ = 0.8.
standard deviations are somewhat different, the proposed test is noticeably less powerful
than the traditional test, even when both sample sizes at 100. When the standard deviations
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are very different, the overlap test is not very powerful at all, regardless of sample size. It
is helpful to look at some graphs of the power functions to help us visualize these findings.
In Figure 5.2, we include all the cases where nR = nE = 100. The red indicates the
case where σR = σE = 1. The gold indicates the case where σR = 1 and σE = 1.5. The
green indicates the case where σR = 1 and σE = 2. Throughout all colors, the dotted line
represents traditional testing and the solid line represents the overlap testing.
We notice that the lines are rather close together and interpret that our proposed
overlap test does quite well when the standard deviations are equal and both sample sizes
are large. The gold has a noticeable disparity in power. Our proposed test is markedly less
powerful than traditional testing when the standard deviations are somewhat different
(meaning that σR = 1 and σE = 1.5). The green has a gap in power so severe, that the
overlap test loses its usefulness completely when the standard deviations are very different
(σR = 1 and σE = 2.)
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Figure 5.2: Both sample sizes at 100 from normal
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This pattern of the overlap test performing very nicely for equal standard deviations,
moderately nicely for somewhat different standard deviations and very poorly for very different standard deviations continued to appear even as the sample size was altered. Figure
5.3 includes all the cases where nR = nE = 50 and Figure 5.4 includes all the cases where
nR = 50 and nE = 100. If any lesson can be learned from altering the sample size, it is
that all cases, both traditional and overlap, are less powerful when the sample sizes are not
both set at 100.
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Figure 5.3: Both sample sizes at 50 from normal
At this stage, one might question the utility of the overlap test since all indications so
far are telling us the proposed test is not as powerful as traditional tests. In some sense,
we should not expect to see an improvement in power when we sample from a normal
population because it is known that the standard test is uniformly most powerful. We need
to try sampling from non-normal populations in order to see situations where the overlap
test proves its worth.
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Figure 5.4: Sample size ratio is 2:1 from normal
5.4

S AMPLING FROM χ2 (1) P OPULATIONS –M ETHODS

Just as with the normal case, we ran simulations when nR = nE = 100, when nR =
nE = 50 and when when nR = 50, nE = 100. For ease, we will sample the reference from
a shifted chi-squared distribution. In particular, the reference is chosen from χ2 (k) − k and
the experimental is chosen from χ2 (k) − k − δN I + ξ where k = 1. The discussion from the
ˆ is performed analogously.
previous section about obtaining ∆N I and estimating var(∆)
Here are the steps taken:
1. Specify k, nR , nE , δN I and ξ.
2. Generate XR ∼ χ2 (k) − k and XE ∼ χ2 (k) − k − δN I + ξ with sample size nR and
nE , respectively.
ˆ using the kernel functions.
3. Obtain ∆
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ˆ using bootstrap samples.
4. And var(
ˆ ∆),
5. Get the test statistic, Z.
6. Repeat steps 2 through 5 over M times.
7. Obtain power, or P (Type I), depending on ξ, as the proportion of times the hypothesis is rejected.
Unlike with the normal case, we did not consider various standard deviations. In
fact, the experimental distribution is a horizontal translate of the reference distribution so
it inherits the same standard deviation. With less cases to show, we can fit all choices of ξ
into a single table. The graphs will be less busy as well. Each one will show just two lines
instead of six.

5.5

S AMPLING FROM χ2 (1) P OPULATIONS –R ESULTS

Table 5.6 has two numbers in each cell. Again, numbers inside the parentheses represent the traditional two-sample hypothesis test while the numbers outside the parentheses
represent the new proposed hypothesis test. It appears the overlap test is more powerful
than the standard test. This is easier to see with graphs.
χ2 (1)

nR = nE = 100

nR = nE = 50

nR = 50, nE = 100

ξ=0

(0.048) 0.049

(0.053) 0.0525

(0.0482) 0.053

ξ = 0.05

(0.094) 0.096

(0.075) 0.0525

(0.077) 0.087

ξ = 0.2

(0.266) 0.370

(0.182) 0.221

(0.234) 0.336

ξ = 0.5

(0.805) 0.977

(0.587) 0.822

(0.6606) 0.930

ξ = 0.8

(0.979) 1.000

(0.878) 0.962

(0.934) 0.996

Table 5.6: Probability of type I error and power from χ2 (1), ξ ∈ {0, 0.05, 0.2, 0.5, 0.8}.
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Figure 5.5 is very encouraging for our proposed test. It is noticeably more powerful in
the setting where nR = nE = 100, particularly as we look beyond values of ξ = 0.05. This
noticeable improvement is also evident in Figure 5.6 where nR = nE = 50 and in Figure
5.7 where nR = 50 and nE = 100. These results suggest that the overlap test is better at
detecting non-inferiority than the standard test in at least some settings. Now we turn our
attention to another chi-squared, but this time, with k = 3.
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Figure 5.5: Both sample sizes at 100 from chi-squared 1 df
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Figure 5.6: Both sample sizes at 50 from chi-squared 1 df
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5.6

S AMPLING FROM χ2 (3) P OPULATIONS –M ETHODS

While the previous section utilized the chi-squared distribution with just one degree
of freedom, we now consider 3 degrees of freedom. In other words, k = 3, but no other
major changes are made. In particular, the reader may consult the list of steps given in the
previous section and replace everywhere k = 1 with k = 3. However, since there is more
spread, in this case, it is necessary to view slightly larger values of ξ in order to observe the
power tending towards 1.
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5.7

S AMPLING FROM χ2 (3) P OPULATIONS –R ESULTS

With k = 3 degrees of freedom, the overlap test is noticeably more powerful than
the traditional 2-means test for all cases. Each entry of Table 5.7 has the value inside the
parentheses, which comes from a standard test, which is smaller than the value outside the
parentheses which comes from the overlap test.
In Figures 5.8 through 5.10 display this with a moderately sized gap between the
power for the overlap test in solid red and the standard test in dotted red. Interestingly, the
gap is actually smaller for smaller values of ξ and larger for larger values of ξ. Thus, the
advantage of using the overlap test becomes greater when the experimental population is
well within the non-inferiority region.
χ2 (3)

nR = nE = 100

nR = nE = 50

nR = 50, nE = 100

This ξ = 0

(0.048) 0.054

(0.046) 0.068*

(0.042) 0.061

ξ = 0.05

(0.063) 0.110

(0.068) 0.086*

(0.064) 0.078

ξ = 0.2

(0.147) 0.176

(0.118) 0.166*

(0.118) 0.136

ξ = 0.5

(0.448) 0.534

(0.346) 0.372

(0.333) 0.379

ξ = 0.8

(0.693) 0.736

(0.461) 0.620

(0.484) 0.599

ξ = 1.1

(0.724) 0.932

(0.616) 0.853

(0.631) 0.815

Table 5.7: Probability of type I error and power from χ2 (3), ξ ∈ {0, 0.05, 0.2, 0.5, 0.8, 1.1}.
(*indicates run with M = 500.)
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Figure 5.8: Both sample sizes at 100 from chi-squared 3 df
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Figure 5.9: Both sample sizes at 50 from chi-squared 3 df
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Figure 5.10: Sample size ratio is 2:1 from chi-squared 3 df
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5.8

S AMPLING FROM E XPONENTIAL P OPULATIONS –M ETHODS

Again, we we ran simulations when nR = nE = 100, when nR = nE = 50 and
when when nR = 50, nE = 100. The reference is chosen from Exp(λ) − λ1 , a shifted
exponential, and the experimental is chosen from Exp(λ) −

1
λ

− δN I + ξ where λ = 1.

Here are the steps taken in the exponential case:
1. Specify λ, nR , nE , δN I and ξ.
2. Generate XR ∼ Exp(λ) − λ1 and XE ∼ Exp(λ) − λ1 − δN I + ξ with sample size nR
and nE , respectively.
ˆ using the kernel functions.
3. Obtain ∆
ˆ using bootstrap samples.
4. And var(
ˆ ∆),
5. Get the test statistic, Z.
6. Repeat steps 2 through 5 over M times.
7. Obtain power, or P (Type I), depending on ξ, as the proportion of times the hypothesis is rejected.

37
5.9

S AMPLING FROM E XPONENTIAL P OPULATIONS –R ESULTS

Table 5.9 again has two numbers in each cell with the numbers inside the parentheses representing the traditional and the numbers outside the parentheses representing the
proposed test. Just as in the chi-squared case, there is evidence the proposed test is more
powerful.
On a cautionary note, one should be careful comparing too closely with the chisquared case. There was an attempt to “smooth” the power function a bit more than previous by considering an additional point at ξ = .3. In the results section, the graphs will
indeed appear smoother, in both the traditional and overlap power functions. One consequence of the extra information is that the gap between dotted and solid line may appear
smaller than with chi-squared, but it is actually due to the added point.
Exp(1)

nR = nE = 100

nR = nE = 50

nR = 50, nE = 100

ξ=0

(0.0470) 0.0585

(0.0560) 0.0565

(0.0515) 0.0470

ξ = 0.05

(0.1115) 0.1120

(0.0950) 0.0955

(0.0870) 0.0940

ξ = 0.2

(0.4235) 0.5195

(0.2710) 0.3220

(0.3030) 0.4280

ξ = 0.3

(0.6985) 0.8075

(0.4505) 0.5680

(0.5400) 0.7145

ξ = 0.5

(0.9685) 0.9945

(0.8105) 0.9045

(0.8865) 0.9740

ξ = 0.8

(0.9995) 1.0000

(0.9885) 0.9965

(0.9960) 0.9995

Figures 5.11 through 5.13 indicate the overlap test is more powerful than standard
testing. The gap between the dotted and solid line is even more evident when the sample
sizes are unequal.
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Figure 5.11: Both sample sizes at 100 from exponential, λ = 1
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Figure 5.13: Sample size ratio is 2:1 from exponential, λ = 1
5.10

C ONCLUDING R EMARKS

Non-inferiority testing is a popular and widely used method of testing a claim about
comparative effectiveness. Vaccines, medications, and therapies can be compared to existing ones in clinical trials, either two-armed, or three-armed with appropriate choices for
the non-inferiority margin. Both frequentest and Baysian approaches are in use.
This thesis proposes a novel way of conducting such tests that requires little or no
knowledge about the underlying distribution. Instead, the test relies on computing the
estimated overlap from the kernel density arising from two samples. When the underlying
distribution was normal with the same variance, the new test did quite well, almost as well
as the standard test. However, for normal distributions with different standard deviations,
the new test was less powerful the more unequal the standard deviations became. This trend
held regardless of sample size considerations.
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The overlap test shined brightest when we sampled from non-normal, skewed populations. Whether we sampled from a chi-squared distribution or from an exponential distribution, the overlap test showed itself to be more powerful than the standard test. This trend
also held regardless of sample size considerations. It would be interesting, in the future to
replicate these same simulations with other distributions or other smaller sample size.
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